There have been technological advances in diabetes care in the last decade, including the introduction of factory-calibrated continuous glucose monitors (CGMs) and their integration through computerised algorithms to insulin pumps, creating closed-loop systems or automated insulin delivery (AID) systems. This evidence concerns the gene INS and diabetes mellitus.